News News & Publications IGM Biosciences to Present at Two Upcoming Investor Conferences February, 2020 Read More... IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis January, 2020 Read More... IGM-2323: High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release December, 2019 Read More... Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies November, 2019 Read More... A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions November, 2019 Read More... IGM Biosciences to Present at Three Upcoming Investor Conferences November, 2019 Read More... IGM Biosciences Announces Third Quarter 2019 Financial Results November, 2019 Read More... IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma October, 2019 Read More... IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares September, 2019 Read More... IGM Biosciences Announces Pricing of Initial Public Offering September, 2019 Read More... « Previous 1 2 3 4 Next »
